Faster and more flexible biomanufacturing models are necessary to reduce the cost of biologics, says Just Biotherapeutics which is building a deployable modular facility in China.
The biosimilars space is becoming more crowded as new players are attracted by reduced development costs and growing market confidence, according to a panel of experts.
Looking for a full-on partnership with Pfizer or a no-strings-attached manufacturing deal? Either way prepare for a tough screening process and don't be located too far from an airport.
NICE’s highly specialised technologies programme has recommended Alexion’s monoclonal antibody (mAb) Soliris despite receiving no justification for the £340,000 ($513,000) price per patient.
Catalent has replaced all stainless steel bioreactors at its biologics facility in Middleton, Wisconsin with single-use techs citing cost and flexibility advantages.
